首页> 美国卫生研究院文献>World Journal of Hepatology >Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

【2h】

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

机译：与新型直接作用抗病毒药相比聚乙二醇干扰素联合利巴韦林治疗丙型肝炎病毒阳性银屑病患者的结果评估

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

摘要
著录项
相似文献
相关主题

摘要

AIMTo evaluate the outcomes in biological treatment and quality of life of psoriatic patients with chronic hepatitis C (CHC) treated with new Direct-Acting Antiviral agents (DAAs) compared to pegylated interferon-2α plus ribavirin (P/R) therapy.

机译：目的：与聚乙二醇干扰素-2α联合利巴韦林（P / R）治疗相比，用新型直接作用抗病毒药物（DAA）治疗的慢性丙型肝炎（CHC）银屑病患者的生物学治疗结果和生活质量进行评估。

著录项

期刊名称 World Journal of Hepatology
作者
Giovanni Damiani; Chiara Franchi; Paolo Pigatto; Andrea Altomare; Alessia Pacifico; Stephen Petrou; Sebastiano Leone; Maria Caterina Pace; Marco Fiore;
展开▼
作者单位

展开▼
年(卷),期 2018(10),2
年度 2018
页码 329–336
总页数 9
原文格式 PDF
正文语种
中图分类外科学;
关键词
Hepatitis C virus New Direct-Acting Antiviral agents Psoriasis Biological disease modifying drugs;

机译：丙型肝炎病毒;新型直接作用抗病毒药;牛皮癣;生物疾病改良药;

相似文献

外文文献
中文文献
专利

1. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: A new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C [J] . MaekawaS., EnomotoN. Journal of gastroenterology . 2014,第1期

机译：每日一次的simeprevir与聚乙二醇化干扰素和利巴韦林联用：直接作用抗病毒药物治疗慢性丙型肝炎时代的新视野
2. Ribavirin plasma level is an independent predictor for sustained virologic response in difficult to treat hepatitis C-infected patients treated with direct-acting antivirals plus ribavirin combination (HepNed study 002) [J] . Lieveld Faydra I., van Tilborg Marjolein, Smolder Elise J., Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2016,第S1期

机译：利巴韦林血浆水平是难以治疗用直接作用抗病毒药肽加密素组合治疗的丙型肝炎C感染患者持续的病毒性反应的独立预测因素（Hepned研究002）
3. French Hepatitis C (HCV) Patients Treated with Anti-viral Combinations Containing Pegylated Interferon (IFN), Ribavirin (RBV), Sofosbuvir (SOF), Ledipasvir (LDV), Velpatasvir (VEL) and/or Voxilaprevir (VOX): The Impact of Treatment on Patient-Reported Outcomes (PROs) [J] . Cacoub Patrice P., Bourliere Marc, Asselah Tarik, Hepatology: Official Journal of the American Association for the Study of Liver Diseases . 2017,第Suppla1期

机译：法国丙型肝炎（HCV）含有聚乙二醇干扰素（IFN），利巴韦林（RBV），Sofosbuvir（SOF），LEDIPASVIR（LDV），VELPATASVIR（VEL）和/或VoxILAPREVIR（VOX）的抗病毒组合患者：影响对患者报告的结果（专业）的治疗
4. High Prevalence of Fatigue and Depression in HIV/Hepatitis C Co-infected Patients Treated with Pegylated Interferon/ Ribavirin [C] . K. Jones, A. Talal, S. Ferrando International AIDS Conference . 2004

机译：用聚乙二醇化干扰素/利巴韦林治疗的艾滋病毒/丙型肝炎COR感染患者疲劳和抑郁症高患病率
5. The meaning of adherence among veterans receiving pegylated interferon and ribavirin antiviral treatment for chronic hepatitis C. [D] . Phillips, Frances Hinshaw. 2011

机译：接受聚乙二醇干扰素和利巴韦林抗病毒治疗的慢性丙型肝炎退伍军人依从性的含义。
6. Anaemia predictors in patients with chronic hepatitis C treated with ribavirin and direct-acting antiviral agents [O] . Emilio Molina-Cuadrado, Héctor Mateo-Carrrasco, Antonio Collado, 2018

机译：利巴韦林和直接作用抗病毒药治疗的慢性丙型肝炎患者贫血的预测因素
7. Once-daily simeprevir in combination with pegylated-interferon and ribavirin: a new horizon in the era of direct-acting antiviral agent therapy for chronic hepatitis C [O] . Shinya Maekawa, Nobuyuki Enomoto 2013

机译：每日一次SimePrevir与Pegymated-Interferon和利巴韦林组合：一种新的耐催化剂治疗中的新地平线，慢性丙型肝炎

Outcomes assessment of hepatitis C virus-positive psoriatic patients treated using pegylated interferon in combination with ribavirin compared to new Direct-Acting Antiviral agents

摘要

著录项

相似文献

相关主题

期刊订阅